CAN IT BE USED AND ACCESSED?

Five markets. Five access checks.

A licence, a positive assessment and practical health service access answer different questions. Peptide Readiness tracks each route separately across England, Wales, Scotland, Northern Ireland and the Republic of Ireland.

01 · LICENCEIs this exact product and indication authorised?

02 · ASSESSMENTWhat has the relevant national body recommended?

03 · ACCESSIs there a funded and operational route?

04 · GOVERNANCEWhat professional and local controls still apply?

LAUNCH MARKET

England

Licence: MHRA marketing authorisation is assessed at UK product and indication level.
Assessment: NICE technology appraisal and guideline activity must be checked separately from authorisation.
Practical access: NHS England commissioning, eligibility, service capacity and local formulary decisions determine practical access.

Initial commercial focus: private clinic governance, specialist pharmacy and NHS pathway intelligence.

LAUNCH MARKET

Wales

Licence: MHRA authorisation applies across the UK, subject to the exact product, formulation and indication.
Assessment: NICE technology appraisal guidance applies in England and Wales. AWMSG may assess medicines where suitable NICE advice is not available.
Practical access: NHS Wales implementation, All Wales advice and local service arrangements require a distinct access check.

Initial commercial focus: NHS Wales access differences, clinic governance and pharmacy evidence checks.

LAUNCH MARKET

Scotland

Licence: MHRA authorisation applies across the UK, subject to the authorised product and indication.
Assessment: The Scottish Medicines Consortium advises NHS Scotland on the clinical and cost effectiveness of newly licensed medicines.
Practical access: SMC advice and NHS board formulary or service arrangements determine routine practical access.

Initial commercial focus: SMC decisions, NHS board implementation and specialist clinic readiness.

LAUNCH MARKET

Northern Ireland

Licence: Since 1 January 2025, the MHRA generally licenses medicines across the whole UK under the Windsor Framework arrangements.
Assessment: National guidance and HSC Northern Ireland medicines access processes must be checked separately from the UK licence.
Practical access: HSC commissioning, regional medicines management and formulary arrangements determine routine access.

Initial commercial focus: Windsor Framework clarity, HSC access and cross border professional questions.

LAUNCH MARKET

Republic of Ireland

Licence: Irish availability requires an authorisation valid in Ireland through the applicable HPRA or European route.
Assessment: The NCPE advises the HSE on comparative effectiveness and value for money. Its advice is not the reimbursement decision.
Practical access: The HSE decides reimbursement. Scheme listing, hospital funding and implementation remain separate access questions.

Initial commercial focus: Irish authorisation, NCPE status, HSE reimbursement and cross border comparison.

CURRENT UK BASELINE

Lawful clinical precedents

These examples retain their source mapped UK position. Nation specific access fields will be published only after the relevant national source has been checked.

LAWFUL CLINICAL PRECEDENT

Semaglutide

Type 2 diabetes and weight management

GLP-1 peptide

NICENICE recommendations within defined criteriaNHSNHS access exists and is pathway constrained

Current NICE source

LAWFUL CLINICAL PRECEDENT

Tirzepatide

Type 2 diabetes and weight management

GIP / GLP-1 peptide

NICENICE TA1026 recommendationNHSPhased NHS implementation and prioritisation

Current NICE source

LAWFUL CLINICAL PRECEDENT

Liraglutide

Type 2 diabetes and weight management

GLP-1 peptide

NICENICE TA664 recommendation for a defined pathwayNHSSpecialist NHS access within criteria

Current NICE source

LAWFUL CLINICAL PRECEDENT

Setmelanotide

Defined genetic obesity syndromes

MC4 receptor agonist peptide

NICENICE highly specialised recommendationsNHSSpecialist NHS access for eligible populations

Current NICE source

LAWFUL CLINICAL PRECEDENT

Teduglutide

Short bowel syndrome

GLP-2 analogue peptide

NICENICE TA804 recommendationNHSSpecialist access subject to criteria and commissioning

Current NICE source

LAWFUL CLINICAL PRECEDENT

Abaloparatide

Osteoporosis after menopause at very high fracture risk

PTHrP analogue peptide

NICENICE TA991 recommendationNHSNHS access within the recommendation and commercial arrangement

Current NICE source

LAWFUL CLINICAL PRECEDENT

Somatropin / somapacitan

Diagnosed growth hormone deficiency and defined growth disorders

Growth hormone therapeutics

NICENICE recommendations exist for defined populationsNHSSpecialist endocrine and shared care pathways

Current NICE source

LAWFUL CLINICAL PRECEDENT

Teriparatide

Selected osteoporosis populations

PTH analogue peptide

NICENICE recommendation for defined secondary prevention populationsNHSAccess within applicable osteoporosis pathways

Current NICE source

This page describes product and pathway status. It is not a prescribing recommendation and does not replace the current product information, national assessment, local formulary, commissioning policy or professional judgement.